Comments
Loading...

Adaptive Biotechnologies Analyst Ratings

ADPTNASDAQ
Logo brought to you by Benzinga Data
$7.41
-0.53-6.68%
At close: -
$7.04
-0.37-4.99%
After Hours: 4:14 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$12.00
Lowest Price Target1
$6.00
Consensus Price Target1
$9.14

Adaptive Biotechnologies Analyst Ratings and Price Targets | NASDAQ:ADPT | Benzinga

Adaptive Biotechnologies Corp has a consensus price target of $9.14 based on the ratings of 7 analysts. The high is $12 issued by Scotiabank on February 13, 2025. The low is $6 issued by JP Morgan on August 2, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Piper Sandler, and Scotiabank on March 21, 2025, February 20, 2025, and February 13, 2025, respectively. With an average price target of $10.67 between Goldman Sachs, Piper Sandler, and Scotiabank, there's an implied 51.52% upside for Adaptive Biotechnologies Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Nov 24
1
Dec 24
1
Jan
1
Feb
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.4
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Goldman Sachs
Piper Sandler
Scotiabank
BTIG
JP Morgan

1calculated from analyst ratings

Analyst Ratings for Adaptive Biotechnologies

Buy NowGet Alert
03/21/2025Buy Now27.84%Goldman Sachs
Salveen Richter51%
$8 → $9UpgradeNeutral → BuyGet Alert
02/20/2025Buy Now56.25%Piper Sandler
David Westenberg59%
$7 → $11ReiteratesOverweight → OverweightGet Alert
02/13/2025Buy Now70.45%Scotiabank
Sung Ji Nam45%
$10 → $12MaintainsSector OutperformGet Alert
01/28/2025Buy Now6.53%Goldman Sachs
Salveen Richter51%
$5.5 → $7.5MaintainsNeutralGet Alert
12/18/2024Buy Now27.84%BTIG
Mark Massaro69%
$8 → $9MaintainsBuyGet Alert
11/11/2024Buy Now-0.57%Piper Sandler
David Westenberg59%
$6 → $7MaintainsOverweightGet Alert
10/02/2024Buy Now13.64%BTIG
Mark Massaro69%
$7 → $8MaintainsBuyGet Alert
08/02/2024Buy Now-14.77%JP Morgan
Rachel Vatnsdal62%
$5 → $6MaintainsOverweightGet Alert
05/08/2024Buy Now-28.98%JP Morgan
Rachel Vatnsdal62%
$8 → $5MaintainsOverweightGet Alert
04/04/2024Buy Now-28.98%BTIG
Mark Massaro69%
$6 → $5MaintainsBuyGet Alert
02/16/2024Buy Now-28.98%Goldman Sachs
Salveen Richter51%
$11 → $5MaintainsNeutralGet Alert
02/15/2024Buy Now13.64%JP Morgan
Rachel Vatnsdal62%
$11 → $8MaintainsOverweightGet Alert
11/13/2023Buy Now-14.77%Piper Sandler
David Westenberg59%
$13 → $6MaintainsOverweightGet Alert
11/10/2023Buy Now56.25%JP Morgan
Rachel Vatnsdal62%
$12 → $11MaintainsOverweightGet Alert
10/24/2023Buy Now42.05%Morgan Stanley
Tejas Savant50%
$13 → $10MaintainsEqual-WeightGet Alert
10/16/2023Buy Now84.66%Piper Sandler
David Westenberg59%
$14 → $13MaintainsOverweightGet Alert
08/08/2023Buy Now98.86%Piper Sandler
David Westenberg59%
$15 → $14MaintainsOverweightGet Alert
08/04/2023Buy Now84.66%Morgan Stanley
Tejas Savant50%
$14 → $13MaintainsEqual-WeightGet Alert
05/05/2023Buy Now98.86%Morgan Stanley
Tejas Savant50%
$15 → $14MaintainsEqual-WeightGet Alert
02/16/2023Buy Now113.07%Morgan Stanley
Tejas Savant50%
$16 → $15MaintainsEqual-WeightGet Alert
02/15/2023Buy Now-0.57%Credit Suisse
Dan Leonard56%
→ $7Reiterates → UnderperformGet Alert
01/05/2023Buy Now113.07%Scotiabank
Sung Ji Nam45%
→ $15Initiates → Sector OutperformGet Alert
12/21/2022Buy Now98.86%Piper Sandler
David Westenberg59%
$7.5 → $14UpgradeNeutral → OverweightGet Alert
11/07/2022Buy Now127.27%Morgan Stanley
Tejas Savant50%
$17 → $16MaintainsEqual-WeightGet Alert
10/26/2022Buy Now6.53%Piper Sandler
David Westenberg59%
$12 → $7.5MaintainsNeutralGet Alert
08/25/2022Buy Now13.64%Credit Suisse
Dan Leonard56%
→ $8Initiates → UnderperformGet Alert
08/17/2022Buy Now70.45%Piper Sandler
David Westenberg59%
$7.5 → $12MaintainsNeutralGet Alert
06/03/2022Buy Now6.53%Piper Sandler
David Westenberg59%
→ $7.5Initiates → NeutralGet Alert
05/24/2022Buy Now42.05%Goldman Sachs
Salveen Richter51%
$14 → $10MaintainsNeutralGet Alert
05/06/2022Buy Now155.68%Morgan Stanley
Tejas Savant50%
$27 → $18MaintainsEqual-WeightGet Alert

FAQ

Q

What is the target price for Adaptive Biotechnologies (ADPT) stock?

A

The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by Goldman Sachs on March 21, 2025. The analyst firm set a price target for $9.00 expecting ADPT to rise to within 12 months (a possible 27.84% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?

A

The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by Goldman Sachs, and Adaptive Biotechnologies upgraded their buy rating.

Q

When was the last upgrade for Adaptive Biotechnologies (ADPT)?

A

The last upgrade for Adaptive Biotechnologies Corp happened on March 21, 2025 when Goldman Sachs raised their price target to $9. Goldman Sachs previously had a neutral for Adaptive Biotechnologies Corp.

Q

When was the last downgrade for Adaptive Biotechnologies (ADPT)?

A

There is no last downgrade for Adaptive Biotechnologies.

Q

When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.

Q

Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?

A

While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a upgraded with a price target of $8.00 to $9.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $7.04, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch